60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference
Rhea-AI Summary
60 Degrees Pharmaceuticals (NASDAQ: SXTP), a pharmaceutical company focused on vector-borne disease treatments, has announced an updated schedule for their presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will now take place on Tuesday, September 9, 2025, at 3:30 PM ET at the Lotte New York Palace Hotel.
CEO Dr. Geoff Dow will deliver a live presentation, and the management team will be available for one-on-one meetings during the conference. The presentation will be accessible via webcast for interested investors.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SXTP gained 2.82%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.0% during that session. Argus tracked a trough of -4.7% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $171K to the company's valuation, bringing the market cap to $6M at that time.
Data tracked by StockTitan Argus on the day of publication.
WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today the webcast link and change of date for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, to Tuesday, September 9, 3:30 PM Eastern Time.
Dr. Geoff Dow, 60 Degrees Pharma CEO, will present live and management will conduct one-on-one meetings during the conference.
Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 9, 2025
Time: 3:30 PM ET
Location: Lotte New York Palace Hotel
Webcast: Register
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.
The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.
Media Contact:
Sheila A. Burke
SheilaBurke-consultant@60degreespharma.com
(484) 667-6330
Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com
FAQ
When is 60 Degrees Pharmaceuticals (SXTP) presenting at the H.C. Wainwright Conference?
Who will be presenting for 60 Degrees Pharmaceuticals (SXTP) at the H.C. Wainwright Conference?
What type of meetings will 60 Degrees Pharmaceuticals (SXTP) management conduct at the conference?
What is 60 Degrees Pharmaceuticals' (SXTP) main business focus?
